Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(ACN - Get Report) rated new Market Perform at BMO Capital Markets. $70 price target. Best positioned firm in sector, but held back by valuation.
(ADI - Get Report) downgraded at Sterne from Buy to Neutral. Company is seeing weaker industrial orders and is leveraged to lower consumer spending.
downgraded at BofA/Merrill to Underperform from Buy. Company is facing higher costs. $46 price target.
downgraded at Goldman from Neutral to Sell. Company has less exposure to rising property catastrophe pricing.
downgraded at JPMorgan from Overweight to Neutral. Revised loss projections no longer support sufficient upside potential.
rated new Underweight at Barclays. Company is facing increased competition from Jim Beam.
(BLT - Get Report)
downgraded at Credit Suisse from Outperform to Neutral. $47 price target. Incorporating the Petrohawk acquisition into model.
(CHH - Get Report)
upgraded at Credit Suisse from Underperform to Neutral. $30 price target. Valuation call, as stock price has fallen dramatically.
rated new Outperform at BMO Capital Markets. $86 price target. Company can support attractive growth for a few years.
Corporate Exec. Board
upgraded at Barclays from Neutral to Overweight. $45 price target. Stock appears oversold, as growth should accelerate in the second half of the year.
Corporate Exec. Board upgraded at Deutsche from Hold to Buy. $45 price target. Company is cutting costs, but can still deliver double-digit bookings growth.
(FISV - Get Report)
upgraded at Baird from Neutral to Outperform. Valuation call, based on a $70 price target.
rated new Overweight at Barclays Capital. Jim Beam should help drive near-term growth.
rated new Buy at Citigroup. $21 price target. Potential to be first successful biofuel company.
KiOR rated new Buy at UBS. $28 price target. Strong support from local and US government programs.
downgraded at BofA/Merrill from Buy to Neutral. $34 price target. Company is leveraged to lower GDP growth.
downgraded at Credit Suisse from Outperform to Neutral. $36 price target. Unplanned downtime and tax rates also rising versus forecasts.